©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jun 7, 2016; 22(21): 5114-5121
Published online Jun 7, 2016. doi: 10.3748/wjg.v22.i21.5114
Published online Jun 7, 2016. doi: 10.3748/wjg.v22.i21.5114
Suppository naproxen reduces incidence and severity of post-endoscopic retrograde cholangiopancreatography pancreatitis: Randomized controlled trial
Fariborz Mansour-Ghanaei, Farahnaz Joukar, Zahra Taherzadeh, Homayoon Sokhanvar, Gastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences, Razi Hospital, Rasht 41448-95655, Iran
Tolou Hasandokht, Department of Community Medicine, Guilan University of Medical Sciences, Rasht 41448-95655, Iran
Author contributions: Mansour-Ghanaei F and Joukar F designed the study; Mansour-Ghanaei F, Taherzadeh Z and Sokhanvar H collected data; Joukar F contributed to data analysis; Joukar F and Sokhanvar H supervised the procedure; Mansour-Ghanaei F, Joukar F and Hasandokht T drafted the manuscript; all authors read and approved the final manuscript.
Institutional review board statement: The study was reviewed and approved by the ethics committee of the Gastrointestinal and Liver Diseases Research Center of Guilan University of Medical Science.
Clinical trial registration statement: This study is registered at Iranian Registry of Clinical Trials. The registration identification number is IRCT201105301155N14.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: None declared.
Data sharing statement: No additional data are available.
Correspondence to: Fariborz Mansour-Ghanaei, MD, AGAF, Professor of Gastroenterology, Gastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences, Razi Hospital, Sardar-Jangle Ave., P.O., Rasht 41448-95655, Iran. ghanaei@gums.ac.ir
Telephone: +98-13-33535116 Fax: +98-13-33534951
Received: June 25, 2015
Peer-review started: June 27, 2015
First decision: October 15, 2015
Revised: October 27, 2015
Accepted: January 17, 2016
Article in press: January 18, 2016
Published online: June 7, 2016
Processing time: 340 Days and 4 Hours
Peer-review started: June 27, 2015
First decision: October 15, 2015
Revised: October 27, 2015
Accepted: January 17, 2016
Article in press: January 18, 2016
Published online: June 7, 2016
Processing time: 340 Days and 4 Hours
Core Tip
Core tip: Acute pancreatitis is the most common serious complication of endoscopic retrograde cholangiopancreatography (ERCP); prevention of post-ERCP pancreatitis (PEP) has become more challenging. The use of nonsteroidal anti-inflammatory drugs is effective in this condition. This study evaluated the efficacy of rectally administered naproxen for the prevention of PEP in composition with placebo immediately before ERCP.